#USA #San Francisco #Biomanufacturing #Stämm #High-Throughput

Stämm's Innovative Leap in Biomanufacturing

Stämm has recently unveiled its groundbreaking High-Throughput Bioprocessor (HTB), a game-changing automated platform designed specifically for biomanufacturing. This state-of-the-art technology aims to streamline the production process for adherent and suspension cells, addressing a significant gap in the current manufacturing landscape.

At a time when the demand for more personalized and accessible therapies is on the rise, the HTB represents a crucial step toward overcoming the challenges associated with traditional biomanufacturing systems. These systems often suffer from limitations due to centralized, high-volume production methods that are no longer well-suited to the evolving needs of medical science. The HTB is set to revolutionize the sector by allowing biomanufacturing to be performed anywhere in the world, mitigating the infrastructural constraints that have historically hindered the rapid development of biologics and cell-gene therapies.

A Closer Look at the HTB Technology

Central to the HTB is its innovative Bubble-Free Bioreactor (BFB), which utilizes a customizable, 3D-printed consumable. This novel approach eliminates the need for conventional impellers, allowing nutrient transport and gas exchange through a laminar flow, akin to capillary networks found in living organisms. By avoiding the introduction of bubbles, sparging, or antifoam agents, the HTB minimizes turbulence and hydrodynamic shear stress that can adversely affect sensitive cell populations typical in stirred-tank systems.

The HTB not only supports continuous perfusion but is also equipped with integrated formulation capabilities suitable for applications like adherent cell differentiation. Additionally, its automated counter-sedimentation feature allows for enhanced performance in suspension cultures, making it a versatile tool for researchers.

According to Yuyo Llamazares, the CEO of Stämm, “Biomanufacturing has been constrained by equipment designed for a centralized, high-volume world that no longer reflects where medicine is going.” His vision for the HTB emphasizes eliminating patient wait times for therapies, regardless of their location, as the technology bridges the logistical gap between scientific discoveries and future medical treatments.

Addressing Industry Bottlenecks

The current state of the global cell and gene therapy manufacturing market is characterized by significant bottlenecks; production infrastructures remain centralized and capital-intensive. This traditional model poses challenges for the personalization of advanced therapies, which often demand smaller, tailored batches of products.

The HTB's modular, plug-and-play architecture directly addresses these issues by replacing traditional stainless-steel vessels with snap-in cartridges, thus reducing overhead costs and enabling faster development timelines. This innovation allows manufacturers to extend their reach into underserved areas—effectively lowering development costs per patient, especially for rare diseases and cell therapies.

Available now for process development within Research Use Only (RUO) applications, the HTB is particularly relevant for pharmaceutical and biotech teams focusing on pre-clinical production, CAR-T therapies, stem cell expansion, and monoclonal antibody workflows. Interested parties can connect with Stämm at www.stamm.bio as they evaluate this pioneering technology. A comprehensive technical data review will be shared soon, and Stämm is offering limited early access partnerships.

As the industry evolves and the need for agile, decentralized solutions becomes more pressing, Stämm’s High-Throughput Bioprocessor stands at the forefront of this transformation, poised to enable faster, more effective energy in biomanufacturing. With its innovative technology, Stämm is not just redefining biomanufacturing; it is also paving the way for the future of medicine—a future where patients around the globe can receive timely and effective therapies.